Literature DB >> 22143388

Bone: Effects of bisphosphonates on bone quality components and fracture risk.

Nick Warde.   

Abstract

Entities:  

Year:  2011        PMID： 22143388     DOI： 10.1038/nrrheum.2011.186

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures.

Authors:  Eve Donnelly; Dennis S Meredith; Joseph T Nguyen; Brian P Gladnick; Brian J Rebolledo; Andre D Shaffer; Dean G Lorich; Joseph M Lane; Adele L Boskey
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741
  1 in total
  1 in total

1.  Prolonged alendronate treatment prevents the decline in serum TGF-β1 levels and reduces cortical bone strength in long-term estrogen deficiency rat model.

Authors:  Junjing Jia; Wei Yao; Sarah Amugongo; Mohammad Shahnazari; Weiwei Dai; Yu-An E Lay; Diana Olvera; Elizabeth A Zimmermann; Robert O Ritchie; Chin-Shang Li; Tamara Alliston; Nancy E Lane
Journal:  Bone       Date:  2012-10-23       Impact factor: 4.398
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.